title: Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts.
abstract: The efficacy of azacitidine has been demonstrated in acute myeloid leukemia (AML) patients with 20-30% bone marrow (BM) blasts, but limited data is available on patients with ≥30% blasts. We analyzed 55 newly diagnosed AML patients, treated with azacitidine. The overall response rate was 42%. Median overall survival (OS) was 12.3 months. We confirmed poor-risk cytogenetics, therapy-related AML, performance score ≥2, and white blood cell count ≥15×10(9)/L as independent adverse predictors for OS. The BM blast percentage, however, had no impact on OS (P=0.55). In conclusion, administration of azacitidine is effective in AML patients with 20-30% and >30% BM blasts.
authors.affiliation: Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands.
authors.forename: L H
authors.initials: LH
authors.lastname: van der Helm
authors.forename: N J G M
authors.initials: NJ
authors.lastname: Veeger
authors.forename: M van Marwijk
authors.initials: Mv
authors.lastname: Kooy
authors.forename: A
authors.initials: A
authors.lastname: Beeker
authors.forename: O
authors.initials: O
authors.lastname: de Weerdt
authors.forename: M
authors.initials: M
authors.lastname: de Groot
authors.forename: C
authors.initials: C
authors.lastname: Alhan
authors.forename: M
authors.initials: M
authors.lastname: Hoogendoorn
authors.forename: L
authors.initials: L
authors.lastname: Laterveer
authors.forename: A A
authors.initials: AA
authors.lastname: van de Loosdrecht
authors.forename: J
authors.initials: J
authors.lastname: Koedam
authors.forename: E
authors.initials: E
authors.lastname: Vellenga
authors.forename: G
authors.initials: G
authors.lastname: Huls
mesh_terms: D000208:Acute Disease; D000368:Aged; D000369:Aged, 80 and over; D001374:Azacitidine / Q000008:administration & dosage / Q000627:therapeutic use*; D001853:Bone Marrow / Q000187:drug effects* / Q000473:pathology; D001854:Bone Marrow Cells / Q000187:drug effects* / Q000473:pathology; D002452:Cell Count; D057176:Compassionate Use Trials; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D007951:Leukemia, Myeloid / Q000097:blood / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D017063:Outcome Assessment, Health Care; D012074:Remission Induction; D012189:Retrospective Studies
chemical_list: D001374:Azacitidine